Fetal and Infant Effects of Maternal Buprenorphine Treatment
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This research will track the longitudinal neurobehavioral development of the
buprenorphine-exposed fetus across gestation through 1 month of age in an effort to determine
the safety of this medication for use during gestation, the relationship between maternal
physiologic changes due to buprenorphine administration and newborn functioning, and to
determine potential fetal neurobehavioral markers that may predict Neonatal Abstinence
Syndrome expression and infant neurobehavioral outcome. Comparisons to results from a similar
project in methadone-exposed pregnancies will be made. This proposal seeks to advance the way
the investigators inform the treatment of the opioid dependent woman during pregnancy and her
infant after birth.